Market cap
$671 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 34.81 | 3.50 | -17.90 | -7.88 | -2.32 |
| EBIT | 14.28 | 19.93 | 5.71 | -9.06 | -392.42 |
| Net Profit | 14.28 | 19.93 | 5.71 | -7.11 | -324.47 |
| EPS | 14.34 | 41.63 | 28.69 | 9.76 | -304.72 |
| Book Value | -- | -- | -37.08 | -37.03 | 18.37 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -5,454.53 | -4,421.82 | -4,613.11 | -4,342.44 | -6,566.61 |
| Net Margin
| -- | 12,002.07 | -4,613.11 | -- | -- |
| Return on equity
| -123.96 | -107.37 | -233.88 | -146.81 | -136.88 |
| Return on Capital
| -96.29 | -87.94 | -- | -93.29 | -115.01 |
| Return on Assets
| -71.36 | -68.72 | -63.28 | -62.83 | -79.73 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.96 | 0.27 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
-93.29
|
-115.01
|
-80.59
|
-40.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-233.88
Lower than Peers by 211.87
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-233.88
|
-146.81
|
-136.88
|
-88.19
|
-43.83
|
|
Peer Median
|
-22.01
|
--
|
--
|
--
|
--
|
ROA
-63.28
Lower than Peers by 50.73
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-63.28
|
-62.83
|
-79.73
|
-71.51
|
-36.79
|
|
Peer Median
|
-12.55
|
--
|
--
|
--
|
--
|
EBIT Margin
-4,613.11
Lower than Peers by 4,562.88
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-4,613.11
|
-4,342.44
|
-6,566.61
|
--
|
-2,356.41
|
|
Peer Median
|
-50.23
|
--
|
--
|
--
|
--
|
Net Margin
-4,613.11
Lower than Peers by 4,556.33
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-4,613.11
|
-4,342.44
|
-6,566.61
|
--
|
12,002.07
|
|
Peer Median
|
-56.78
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-17.90
Lower than Peers by 34.00
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-17.90
|
0.55
|
--
|
-1.00
|
--
|
|
Peer Median
|
16.10
|
--
|
--
|
--
|
--
|
EBIT Growth
5.71
Lower than Peers by 6.97
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
5.71
|
-2.69
|
-2.40
|
-55.81
|
25.98
|
|
Peer Median
|
12.68
|
--
|
--
|
--
|
--
|
Net Profit Growth
5.71
Lower than Peers by 2.68
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
5.71
|
-2.69
|
1.14
|
-62.64
|
26.33
|
|
Peer Median
|
8.39
|
--
|
--
|
--
|
--
|
EPS Growth
28.69
Lower than Peers by 2.55
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
28.69
|
0.18
|
0.19
|
-0.62
|
0.27
|
|
Peer Median
|
31.24
|
--
|
--
|
--
|
--
|
Book Value Growth
-52.32
Lower than Peers by 54.46
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-52.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2.14
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
0.96
|
0.27
|
0.10
|
0.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.23
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
0.23
|
0.07
|
0.02
|
0.07
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.05
Lower than Peers by 0.66
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
3.05
|
4.84
|
5.58
|
2.53
|
11.10
|
|
Peer Median
|
3.72
|
--
|
--
|
--
|
--
|
Quick Ratio
3.05
Lower than Peers by 0.62
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
3.05
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.67
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
--
|
--
|
--
|
-10.12
|
|
Peer Median
|
-0.34
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
23.32
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.25
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
0.01
|
0.01
|
0.01
|
--
|
0.02
|
|
Peer Median
|
0.26
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
504.84
|
920.52
|
936.83
|
87.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
-2.57
|
-1.77
|
-4.35
|
-14.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.34
Lower than Peers by 4.56
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
0.34
|
4.27
|
2.26
|
6.48
|
5.71
|
|
Peer Median
|
4.90
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-3.10
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
-3.10
|
-2.32
|
-1.04
|
-4.04
|
-12.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
671
Higher than Peers by 580
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Prime Medicine
|
671
|
--
|
--
|
--
|
--
|
|
Peer Median
|
91
|
--
|
--
|
--
|
--
|